학술논문
EGFR inhibitors plus bevacizumab are superior than EGFR inhibitors alone as first-line setting in advanced NSCLC with EGFR mutations and BIM deletion polymorphisms (BIM-CLICaP)
Document Type
Article
Author
Cardona, A.F.; Rojas, L.; Carranza, H.; Vargas, C.; Ordóñez-Reyes, C.; Ruiz-Patiño, A.; Sotelo, C.; Rodríguez, J.; Ricaurte, L.; Ávila, J.; Mayorga, D.; Archila, P.; Otero, J.; Bermudez, M.; Gamez, T.; Garcia-Robledo, J.E.; Barron, L.Z.; Barrón, F.; Arrieta, O.; Recondo, G.; Corrales, L.; Martín, C.; Rolfo, C.; Mas, L.; Rosell, R.
Source
In: JCO Precision Oncology . (JCO Precision Oncology, 2021, 5:839-848)
Subject
Language
English
ISSN
24734284